Dr. Arnold currently serves as CSO at Biocept. In 2010 he founded AEGEA Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold also serves on the board of directors of Asuragen, as well as on the board of AEGEA. Previously, Dr. Arnold held various senior scientific and management positions at Molecular Biosystems (co-founder), Gen-Probe, Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder). Additionally, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. He is an inventor or co-inventor on 44 issued U.S. patents and more than 140 issued and pending patents worldwide. Dr. Arnold has authored more than 50 scientific publications. He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Combining CTC and ctDNA Platforms from the Same Clinical Samples to Expand Liquid Biopsy Biomarker Content
Thursday, 29 September 2016 at 11:30
Add to Calendar ▼2016-09-29 11:30:002016-09-29 12:30:00Europe/LondonCombining CTC and ctDNA Platforms from the Same Clinical Samples to Expand Liquid Biopsy Biomarker ContentLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Liquid biopsies offer the opportunity to interrogate a number of different target sample types, including ctDNA and CTCs. At Biocept both ctDNA and CTCs are used for identifying medically actionable biomarkers. The combination of these technologies has enabled the clinical validation of an array of biomarkers from single blood samples. These include mutational analysis for EGFR, KRAS, and BRAF, as well as FISH and protein analysis for HER2, FGFR1, MET, ALK, ROS1, ER, PR, AR and PDL-1 across a range of cancer types. In addition, CTCs can be isolated from the microchannel and interrogated using other means, including NGS.
Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2016Liquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-29 11:30:002016-09-29 12:30:00Europe/LondonCombining CTC and ctDNA Platforms from the Same Clinical Samples to Expand Liquid Biopsy Biomarker ContentLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
